Takahide Kikuchi, Parker Pablo M, Wu Michael, Hwang William Y K, Carpenter Paul A, Moravec Carina, Stehr Barbara, Martin Paul J, Rosenthal Perry, Forman Stephen J, Flowers Mary E D
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Biol Blood Marrow Transplant. 2007 Sep;13(9):1016-21. doi: 10.1016/j.bbmt.2007.05.006. Epub 2007 Jul 20.
Keratoconjunctivitis sicca (KCS) occurs in 40%-60% of patients with chronic graft-versus-host-disease (cGVHD) after allogeneic hematopoietic cell transplantation. Although immunosuppressive therapy is the primary treatment of chronic GVHD, ocular symptoms require measures to improve ocular lubrication, decrease inflammation, and maintain mucosal integrity. The liquid corneal bandage provided by a fluid-ventilated, gas-permeable scleral lens (SL) has been effective in mitigating symptoms and resurfacing corneal erosions in patients with KCS related to causes other than cGVHD. We report outcomes in 9 consecutive patients referred for SL fitting for cGVHD-related severe KCS that was refractory to standard treatments. All patients reported improvement of ocular symptoms and reduced the use of topical lubricants after SL fitting resulting from decreased evaporation. No serious adverse events or infections attributable to the SL occurred. The median Ocular Surface Disease Index improved from 81 (75-100) to 21 (6-52) within 2 weeks after SL fitting, and was 12 (2-53) at the time of last contact, 1-23 months (median, 8.0) after SL fitting. Disability related to KCS resolved in 7 patients after SL fitting. The use of SL appears to be safe and effective in patients with severe cGVHD-related KCS refractory to conventional therapies.
干燥性角结膜炎(KCS)发生在异基因造血细胞移植后40%-60%的慢性移植物抗宿主病(cGVHD)患者中。尽管免疫抑制治疗是慢性移植物抗宿主病的主要治疗方法,但眼部症状需要采取措施来改善眼部润滑、减轻炎症并维持黏膜完整性。由流体通气、透气巩膜镜(SL)提供的液体角膜绷带在减轻与cGVHD以外原因相关的KCS患者的症状和修复角膜糜烂方面已显示出效果。我们报告了9例因cGVHD相关严重KCS而转诊进行SL配镜的连续患者的治疗结果,这些患者对标准治疗无效。所有患者均报告眼部症状有所改善,且由于蒸发减少,配镜后局部润滑剂的使用量减少。未发生归因于SL的严重不良事件或感染。配镜后2周内,眼表疾病指数中位数从81(75-100)改善至21(6-52),在最后一次随访时为12(2-53),随访时间为配镜后1-23个月(中位数为8.0个月)。配镜后7例患者与KCS相关的残疾问题得到解决。对于传统治疗无效的严重cGVHD相关KCS患者,使用SL似乎是安全有效的。